Why the study?
Limited data exist regarding the impact of standardized care on cardiogenic shock outcomes over time.
Does standardized team-based care over time improve in-hospital mortality in patients with cardiogenic shock?
Does standardized team-based care over time improve in-hospital mortality in patients with cardiogenic shock?
Standardized team-based care for cardiogenic shock was associated with consistent in-hospital mortality over time despite increasing patient complexity and shifts in mechanical circulatory support use.
Stable mortality despite care shifts; leaves open whether team-based protocols affect cardiogenic shock outcomes.
BACKGROUND AND AIMS: Limited data exist regarding the impact of standardized care on cardiogenic shock (CS) outcomes over time. We aimed to investigate the influence of multidisciplinary management on CS outcomes following implementation of team-based protocols in 2017. METHODS: A total of 1453 consecutive patients enrolled into a single-centre CS registry were divided into two time periods, 2017-2019 versus 2020-2022. Baseline characteristics, management and outcomes were compared. The primary endpoint was adjusted in-hospital mortality. Multivariable regression analysis was performed to evaluate change in outcomes over time. RESULTS: Compared with 2017-2019, more patients with CS were treated in 2020-2022 (930 vs. 523; P < 0.01). They more often presented to the Level 1 centre (52% vs. 45%; P = 0.01), with a higher proportion of heart failure-related CS (72% vs. 58%; P < 0.01) and Society for Cardiovascular Angiography and Interventions B and C CS (64% vs. 49%; P < 0.01). They were less likely to be managed with percutaneous ventricular assist devices (11% vs. 24%; P < 0.01) but more likely to receive veno-arterial extracorporeal membrane oxygenation (14% vs. 4%; P < 0.01) and heart transplantation (9% vs. 4%; P < 0.04). No differences were noted in in-hospital mortality [adjusted odds ratio (aOR) 0.81; 95% confidence interval (CI): 0.56-1.16; P = 0.25], major adverse cardiac and cerebrovascular events (aOR 1.21; 95% CI: 0.87-1.68; P = 0.26), stroke (aOR 1.11; 95% CI: 0.65-1.91; P = 0.71) or renal replacement therapy (aOR 0.95; 95% CI: 0.66-1.37; P = 0.77). CONCLUSIONS: Standardized care for CS was associated with consistent in-hospital mortality over time despite changes in presentation and management. Further research is needed to identify the optimal care model during the vulnerable post-discharge period.
No takes yet. Share an insight, caveat, or question.
Tehrani et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: